BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22431865)

  • 1. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II).
    Anderson JL; Horne BD; Stevens SM; Woller SC; Samuelson KM; Mansfield JW; Robinson M; Barton S; Brunisholz K; Mower CP; Huntinghouse JA; Rollo JS; Siler D; Bair TL; Knight S; Muhlestein JB; Carlquist JF
    Circulation; 2012 Apr; 125(16):1997-2005. PubMed ID: 22431865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
    Anderson JL; Horne BD; Stevens SM; Grove AS; Barton S; Nicholas ZP; Kahn SF; May HT; Samuelson KM; Muhlestein JB; Carlquist JF;
    Circulation; 2007 Nov; 116(22):2563-70. PubMed ID: 17989110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
    van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
    Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
    Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
    Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of warfarin pharmacogenetic algorithms in clinical practice.
    Marin-Leblanc M; Perreault S; Bahroun I; Lapointe M; Mongrain I; Provost S; Turgeon J; Talajic M; Brugada R; Phillips M; Tardif JC; Dubé MP
    Pharmacogenomics; 2012 Jan; 13(1):21-9. PubMed ID: 22176621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 12. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
    Verhoef TI; Ragia G; de Boer A; Barallon R; Kolovou G; Kolovou V; Konstantinides S; Le Cessie S; Maltezos E; van der Meer FJ; Redekop WK; Remkes M; Rosendaal FR; van Schie RM; Tavridou A; Tziakas D; Wadelius M; Manolopoulos VG; Maitland-van der Zee AH;
    N Engl J Med; 2013 Dec; 369(24):2304-12. PubMed ID: 24251360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
    Stergiopoulos K; Brown DL
    JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M; Burnside G; Eriksson N; Jorgensen AL; Toh CH; Nicholson T; Kesteven P; Christersson C; Wahlström B; Stafberg C; Zhang JE; Leathart JB; Kohnke H; Maitland-van der Zee AH; Williamson PR; Daly AK; Avery P; Kamali F; Wadelius M;
    N Engl J Med; 2013 Dec; 369(24):2294-303. PubMed ID: 24251363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
    Gage BF; Eby C; Johnson JA; Deych E; Rieder MJ; Ridker PM; Milligan PE; Grice G; Lenzini P; Rettie AE; Aquilante CL; Grosso L; Marsh S; Langaee T; Farnett LE; Voora D; Veenstra DL; Glynn RJ; Barrett A; McLeod HL
    Clin Pharmacol Ther; 2008 Sep; 84(3):326-31. PubMed ID: 18305455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE; French B; Kasner SE; Johnson JA; Anderson JL; Gage BF; Rosenberg YD; Eby CS; Madigan RA; McBane RB; Abdel-Rahman SZ; Stevens SM; Yale S; Mohler ER; Fang MC; Shah V; Horenstein RB; Limdi NA; Muldowney JA; Gujral J; Delafontaine P; Desnick RJ; Ortel TL; Billett HH; Pendleton RC; Geller NL; Halperin JL; Goldhaber SZ; Caldwell MD; Califf RM; Ellenberg JH;
    N Engl J Med; 2013 Dec; 369(24):2283-93. PubMed ID: 24251361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.